[
  {
    "ts": null,
    "headline": "Moderna opens new vaccine facility in boost for UK pharmaceutical industry",
    "summary": "The plant in Oxfordshire can make up to 100 million doses per year.",
    "url": "https://finnhub.io/api/news?id=81df3737207d6fbb42b4c3c7db7336867a9b38177c9f0de0a0e75f7266f61f73",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758754860,
      "headline": "Moderna opens new vaccine facility in boost for UK pharmaceutical industry",
      "id": 136866427,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The plant in Oxfordshire can make up to 100 million doses per year.",
      "url": "https://finnhub.io/api/news?id=81df3737207d6fbb42b4c3c7db7336867a9b38177c9f0de0a0e75f7266f61f73"
    }
  },
  {
    "ts": null,
    "headline": "Shareholders of Verona Pharma Approve Proposed Acquisition by Merck",
    "summary": "Transaction expected to close on October 7, 2025LONDON, U.K., and RALEIGH, N.C., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, which entered into a definitive agreement on July 8, 2025 relating to its proposed acquisition by Merck & Co., Inc. (NYSE: MRK) (“Merck”) through a wholly owned subsidiary or a nominee, today announced that its shareholders have approved the proposal for Merck to acquire",
    "url": "https://finnhub.io/api/news?id=9e117421ab53a58349c67be8ff7ecfdd50f1d9a18f2a5c03d5d1e2e25bc1b52f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758744300,
      "headline": "Shareholders of Verona Pharma Approve Proposed Acquisition by Merck",
      "id": 136866079,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Transaction expected to close on October 7, 2025LONDON, U.K., and RALEIGH, N.C., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, which entered into a definitive agreement on July 8, 2025 relating to its proposed acquisition by Merck & Co., Inc. (NYSE: MRK) (“Merck”) through a wholly owned subsidiary or a nominee, today announced that its shareholders have approved the proposal for Merck to acquire",
      "url": "https://finnhub.io/api/news?id=9e117421ab53a58349c67be8ff7ecfdd50f1d9a18f2a5c03d5d1e2e25bc1b52f"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Surges 26.5% YTD: Buy, Sell or Hold the Stock?",
    "summary": "Gilead surges 26.5% YTD in 2025 as HIV franchise gains momentum with Yeztugo approval, offsetting cell therapy pressures.",
    "url": "https://finnhub.io/api/news?id=c31f0eb7b444d1d11e453598965583999eac9a879aa88cbb2d0d6643ab1cedac",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758723360,
      "headline": "Gilead Sciences Surges 26.5% YTD: Buy, Sell or Hold the Stock?",
      "id": 136863261,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Gilead surges 26.5% YTD in 2025 as HIV franchise gains momentum with Yeztugo approval, offsetting cell therapy pressures.",
      "url": "https://finnhub.io/api/news?id=c31f0eb7b444d1d11e453598965583999eac9a879aa88cbb2d0d6643ab1cedac"
    }
  },
  {
    "ts": null,
    "headline": "TruTechnologies Appoints Mirador Therapeutics Executive Jordan Zwick to Board of Directors",
    "summary": "DURHAM, N.C., September 24, 2025--TruTechnologies announced Mirador Therapeutics executive Jordan Zwick joined its Board of Directors.",
    "url": "https://finnhub.io/api/news?id=6972ccc7cdc4677812907daeaa7a40e648006a3afe56c3f2475a276b9c0c0251",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758715200,
      "headline": "TruTechnologies Appoints Mirador Therapeutics Executive Jordan Zwick to Board of Directors",
      "id": 136861677,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "DURHAM, N.C., September 24, 2025--TruTechnologies announced Mirador Therapeutics executive Jordan Zwick joined its Board of Directors.",
      "url": "https://finnhub.io/api/news?id=6972ccc7cdc4677812907daeaa7a40e648006a3afe56c3f2475a276b9c0c0251"
    }
  },
  {
    "ts": null,
    "headline": "The Smartest Dividend Stock to Buy With $1,000 Right Now",
    "summary": "Drug makers are out of favor right now, but the industry will survive. Here's one company that stands out as an investment option.",
    "url": "https://finnhub.io/api/news?id=ebc306ebeb1bb9c44e3e8327380a59c0d6187d4366d3fb09bafe16897e87e9d4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758714300,
      "headline": "The Smartest Dividend Stock to Buy With $1,000 Right Now",
      "id": 136861679,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Drug makers are out of favor right now, but the industry will survive. Here's one company that stands out as an investment option.",
      "url": "https://finnhub.io/api/news?id=ebc306ebeb1bb9c44e3e8327380a59c0d6187d4366d3fb09bafe16897e87e9d4"
    }
  },
  {
    "ts": null,
    "headline": "Siemens' AI and Robotics Push Could Be a Game Changer for Siemens (XTRA:SIE)",
    "summary": "Siemens Healthineers and Stryker recently announced a partnership to co-develop robotic systems for neurovascular procedures, aiming to enhance precision and efficiency in stroke and aneurysm care, while Siemens and Merck have agreed to accelerate digital transformation in life sciences by integrating AI and automation into drug discovery and manufacturing. These collaborations highlight Siemens’ increasing emphasis on advanced digital healthcare ecosystems and its intent to shape the future...",
    "url": "https://finnhub.io/api/news?id=8e51210ab81ecf35676df6ef6afd0e1a0720bc9c4dd3c0434a2b1649295869a8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758712701,
      "headline": "Siemens' AI and Robotics Push Could Be a Game Changer for Siemens (XTRA:SIE)",
      "id": 136861680,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Siemens Healthineers and Stryker recently announced a partnership to co-develop robotic systems for neurovascular procedures, aiming to enhance precision and efficiency in stroke and aneurysm care, while Siemens and Merck have agreed to accelerate digital transformation in life sciences by integrating AI and automation into drug discovery and manufacturing. These collaborations highlight Siemens’ increasing emphasis on advanced digital healthcare ecosystems and its intent to shape the future...",
      "url": "https://finnhub.io/api/news?id=8e51210ab81ecf35676df6ef6afd0e1a0720bc9c4dd3c0434a2b1649295869a8"
    }
  },
  {
    "ts": null,
    "headline": "China's Jiangsu Hengrui to grant license for cancer drug to unit of India's Glenmark",
    "summary": "Under the agreement, Hengrui will receive an upfront payment of $18 million and can get milestone payments of up to $1.09 billion from Glenmark Specialty S.A. The Chinese firm will also be eligible for royalties on net sales of the drug in the licensed territories.  The deal gives the Indian company rights to a drug from a class called antibody drug conjugate.  Their targeted approach has led to billions in investment from pharmaceutical giants such as US-based Merck, Roche and AstraZeneca in recent years.",
    "url": "https://finnhub.io/api/news?id=553d42ef2e791d9459a43e2c71476e20791e49daaf073d6169d83e1904c21053",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758708756,
      "headline": "China's Jiangsu Hengrui to grant license for cancer drug to unit of India's Glenmark",
      "id": 136861681,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Under the agreement, Hengrui will receive an upfront payment of $18 million and can get milestone payments of up to $1.09 billion from Glenmark Specialty S.A. The Chinese firm will also be eligible for royalties on net sales of the drug in the licensed territories.  The deal gives the Indian company rights to a drug from a class called antibody drug conjugate.  Their targeted approach has led to billions in investment from pharmaceutical giants such as US-based Merck, Roche and AstraZeneca in recent years.",
      "url": "https://finnhub.io/api/news?id=553d42ef2e791d9459a43e2c71476e20791e49daaf073d6169d83e1904c21053"
    }
  },
  {
    "ts": null,
    "headline": "3 Dividend Stocks Perfect for Millennial Investors",
    "summary": "All three of these names are not only built to last, they're being rebuilt to thrive for at least a few more decades.",
    "url": "https://finnhub.io/api/news?id=4d1cefa806b054d694e87fde4ca4352fe21ff54c821ef16104136d57875c2585",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758701700,
      "headline": "3 Dividend Stocks Perfect for Millennial Investors",
      "id": 136861682,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "All three of these names are not only built to last, they're being rebuilt to thrive for at least a few more decades.",
      "url": "https://finnhub.io/api/news?id=4d1cefa806b054d694e87fde4ca4352fe21ff54c821ef16104136d57875c2585"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's boss calls UK the 'worst' European country for drug prices",
    "summary": "LONDON (Reuters) -Eli Lilly Chief Executive Dave Ricks said Britain was \"probably the worst country in Europe\" for drug prices in an interview with the Financial Times, intensifying pressure on the government to improve market conditions for drugmakers.  The remarks are part of a broader backlash from pharmaceutical giants, including Merck and AstraZeneca, who have paused or scaled back investments in Britain over the challenging environment.  Ricks said Britain would miss out on new drugs if it did not raise prices and scrap a rebate scheme which requires companies to contribute a portion of their UK drug revenue to the state-run NHS.",
    "url": "https://finnhub.io/api/news?id=299e5d1ae0fcaa078a7352e2f66df3c7435c3b5b79781559c07c82aaaa04bb76",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758701500,
      "headline": "Eli Lilly's boss calls UK the 'worst' European country for drug prices",
      "id": 136861536,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "LONDON (Reuters) -Eli Lilly Chief Executive Dave Ricks said Britain was \"probably the worst country in Europe\" for drug prices in an interview with the Financial Times, intensifying pressure on the government to improve market conditions for drugmakers.  The remarks are part of a broader backlash from pharmaceutical giants, including Merck and AstraZeneca, who have paused or scaled back investments in Britain over the challenging environment.  Ricks said Britain would miss out on new drugs if it did not raise prices and scrap a rebate scheme which requires companies to contribute a portion of their UK drug revenue to the state-run NHS.",
      "url": "https://finnhub.io/api/news?id=299e5d1ae0fcaa078a7352e2f66df3c7435c3b5b79781559c07c82aaaa04bb76"
    }
  }
]